PL-D 31

General Information


DRACP ID  DRACP02249

Peptide Name   PL-D 31

Sequence  RWWIRIRWH

Sequence Length  9

UniProt ID  Not available

PubChem CID  Not available

Origin  Synthetic

Type  Synthetic peptide

Classification

  

Active ACP



Activity Information


Cell Line Disease Cancer Classified Activity Assay Testing Time Literature
THP-1 Childhood acute monocytic leukemia; Acute monoblastic/monocytic leukemia Leukemia IC50=181.8 µM Resazurin assay 72 h 1

Hemolytic Activity  Not available

Normal (non-cancerous) Cytotoxicity  Not available

Target  Not available

Affinity  Not available

Mechanism  Not available

Nature  Anticancer; Antimicrobial



Structure Information


PDB ID  Not available

Predicted Structure  DRACP02249

Helicity  Not available

Linear/Cyclic  Linear

Disulfide/Other Bond  Not available

N-terminal Modification  Free

C-terminal Modification  Free

Other Modification  None

Chiral  L



Physicochemical Information


Formula  C69H97N23O10

Absent amino acids  ACDEFGKLMNPQSTVY

Common amino acids  RW

Mass  155155

Pl  12.8

Basic residues  4

Acidic residues  0

Hydrophobic residues  5

Net charge  4

Boman Index  -3259

Hydrophobicity  -115.56

Aliphatic Index  86.67

Half Life 
  Mammalian: 5.5 hour
  Yeast: 3 min
  E.coli: 2 min

Extinction Coefficient cystines  16500

Absorbance 280nm  2062.5

Polar residues  0

Amino acid distribution



Literature Information


Literature 1

Pubmed ID 23478953

Title  Targeting Mycobacterium tuberculosis and other microbial pathogens using improved synthetic antibacterial peptides

Doi 10.1128/AAC.00175-13

Year  2013

Patent

Patent ID Not available

Patent Title  Not available

Other Iinformation  Not available

Other Published ID  Not available




DBAASP ID  DBAASPS_7076

DRACP is developed by Dr.Zheng's team.